Patent Tracker
Applications for patents related to psychedelics have boomed in recent years. Nonprofits, pharmaceutical companies, startups, and academic institutions are all jockeying to patent specific psychedelic compounds and formulations. To help keep tabs on the status of patent applications as they wind their way through the U.S. Patent and Trademark’s review process, BCSP has collaborated on a patent tracker with Psychedelic Alpha, an independent media outlet, community and consultancy firm in the psychedelic field, and Calyx Law, a patent law boutique focusing on cannabis and psychedelics related IP. Read more about the history and process of psychedelic patents here.
430 Patents
DMT
Title
Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
Subject Matter
The present invention relates to compositions comprising N,N-dimethyltryptamine, deuterated N,N-dimethyltryptamine and/or partially deuterated N,N-dimethyltryptamine. In particular, the present invention relates to compositions comprising a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more deuterated N,N-dimethyltryptamine compound selected from .alpha.,.alpha.-dideutero-N,N-dimethyltryptamine and .alpha.,.alpha.,.beta.,.beta.-tetradeutero-N,N-dimethyltryptamine. Additional and alternative compositions of the present invention comprise a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more partially deuterated N,N-dimethyltryptamine compound selected from .alpha.,.beta.,.beta.-trideutero-N,N-dimethyltryptamine, .alpha.,.beta.-dideutero-N,N-dimethyltryptamine, and .alpha.-deutero-N,N-dimethyltryptamine.
LSD
Title
Movement disorders
Subject Matter
A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.
MDMA
Title
Combination product using 3,4-methylenedioxymethamphetamine and carvedilol for the treatment of psychiatric disorders
Subject Matter
A composition for treating an individual while reducing acute adverse effects of an empathogen/entactogen, including effective amounts of the empathogen/entactogen and an adverse effect-reducing agent that blocks adverse effects of the empathogen/entactogen. A method of treating an individual with an empathogen/entactogen and reducing its acute adverse effects, by administering an empathogen/entactogen to the individual, administering an adverse effect-reducing agent to the individual, and reducing the acute adverse effects of the empathogen/entactogen. A method of stopping the acute cardlostimulant and hyperthermic action of an empathogen/entactogen in an individual, by administering an adverse effect-reducing agent to the individual after the individual has taken the empathogen/entactogen and stopping the acute adverse effects of the empathogen/entactogen, A method of treating an individual at risk of cardiovascular events and/or hyperthermia with an empathogen/entactogen.
Psilocybin
Title
Metered dosing compositions and methods of use of psychedelic compounds
Subject Matter
Compositions of psychedelic compounds for use in metered-dosing administration modalities, such as a nasal spray or pressurized metered-dose inhaler.
Psilocybin
Title
Methods for producing tryptamine derivatives
Subject Matter
The disclosure relates to a method for producing a tryptamine derivative of formula (I), wherein the tryptamine derivative (I) is not tryptophan, 4-hydroxytryptamine, N-acetyl-4-hydroxytryptamine, norbaeocystin, baeocystin; psilocybin, psilocin, aeruginascin, halogenated tryptophan, halogenated tryptamine, halogenated N-methylated tryptamine, halogenated N,N-dimethyltryptamine or halogenated Ν,Ν,Ν-trimethyltryptamine; said method comprising providing an indole acceptor of the formula (II), wherein the tryptamine derivative (I) is not tryptophan, 4-hydroxytryptamine, N-acetyl-4-hydroxytryptamine, norbaeocystin, baeocystin; psilocybin, psilocin, aeruginascin, halogenated tryptophan, halogenated tryptamine, halogenated N-methylated tryptamine, halogenated N,N- dimethyltryptamine or halogenated Ν,Ν,Ν-trimethyltryptamine; said method comprising providing an indole acceptor of the formula (II), wherein one or more of Rll, RIV, RV, RVI or RVII is not H and Rill is H or CH2CH2NH2 or CH2CHCOOHNH2; and contacting the indole acceptor with a substituent donor in the precense of one or more enzymes substituting one or more H, OH and/or COOH in the indole acceptor with one or more substituents of the substituent donor.
Psilocybin
Title
Carboxylated psilocybin derivatives and methods of using
Subject Matter
A chemical compound having the psilocybin molecular structure, wherein atleast one component is a carboxyl group or carboxylic acid derivative.
MDMA
Title
Novel short-acting psychoactive compounds of the mdma class
Subject Matter
Novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.
Owner
Mydecine Innovations Group Inc.
Patent Number
WO2023288013Priority Date
07.14.2021
Status
Published
MDMA
Title
Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
Subject Matter
Drug products with improved safety and anti-abuse properties, comprising a matrix of BNDO and an active compound, including MDMA and Ibogaine.
Owner
Pisgah Labs
Patent Number
US10,183,001Priority Date
05.22.2007
Status
Granted 2019-01-22 (expires 2027-10-13)
LSD
Title
Compounds for use in a method of treating, preventing and/or reducing the symptopms of pain
Subject Matter
Using low doses and microdoses (2 to 50 micrograms) of LSD to treat, prevent, or reduce the symptoms of pain.
MDMA
Title
Preparation and utility of substituted amphetamines
Subject Matter
Deuterated amphetamines including MDMA and MDA, processes of their preparation, pharmaceutical compositions thereof, and methods of their use for the treatment and/or management of trauma, e.g., PTSD.
Page 1 of 43